CAS 131086-22-1

Lamivudine-trans (4-amino-1-[(2RS,5RS)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 1-[(2RS,5RS)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine)

CAS : 131086-22-1

Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi

Formule : C₈H₁₁N₃O₃S

Couleur et forme : Off-White Solid

Masse moléculaire : 229.05211

Ref: 45-1A05140

Lamivudine EP Impurity B

CAS : 131086-22-1

Formule : C₈H₁₁N₃O₃S

Couleur et forme : Off-White Solid

Masse moléculaire : 229.25

Ref: 4Z-L-204

Lamivudine EP Impurity B

CAS : 131086-22-1

Formule : C₈H₁₁N₃O₃S

Masse moléculaire : 229.25

Ref: ST-EA-CP-L3002

(+/-)-trans-Lamivudine

CAS : 131086-22-1

Lamivudine is an antiviral drug that belongs to the group of nucleoside analogues. It can be used as a single agent or in combination with other antiviral drugs for the treatment of HIV infection. Lamivudine is a prodrug that is converted to its active form, which inhibits viral DNA synthesis by competing with natural substrates for incorporation into viral DNA by inhibiting viral polymerase activity and causing chain termination. The long-term toxicity of lamivudine has been studied in animals and humans. Although it does not cause any serious side effects, it can cause hepatitis and reactivation of hepatitis B virus (HBV). Lamivudine has been shown to inhibit the IL-2 receptor on T cells, which may contribute to its beneficial effect on HBV.

Formule : C₈H₁₁N₃O₃S

Degré de pureté : Min. 95%

Masse moléculaire : 229.26 g/mol

Ref: 3D-GFA08622

Lamivudine, (+/-)-trans-

CAS : 131086-22-1

Lamivudine, a drug for HIV-1 and HBV, inhibits reverse transcriptase and resembles zalcitabine.

Formule : C₈H₁₁N₃O₃S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 229.26

Ref: TM-T25609